RE:RE:Some Thoughts in Summary",,Can this investment get any more erroded than it has ,,,it must be assumed it certainly can,,,,,it cant even be considered an investment anymore,,,,"
It's very important to draw a clear distinction between an investment and a speculation. It never was an 'investment'. It has always been a 'speculation'. It has never been in human trials let alone provided a proof of concept in humans. It has never been through Phase 1, 2, or 3 trials or reached final regulatory approval and market acceptance. xB3 could be 2 years from clinical trials with an internal product still after a decade of trying. Denali is years ahead of xB3 with Hunter and in trials. Lots of de-risking ahead hopefully; maybe even with Chiesi but we have no visibility into that. I don't know what Hunter data BTI is presenting in Q2 of next year. Maybe there is improvement to address compeition ahead of xB3 as Denaili and behind xB3 such as gene-therapy or potential functional cures. There is competition on all sides.
"Now on life support at .05 cents it becomes at the most a tax loss instrument now or down the road."
Armistice Capital, likely because of Ladenberg Thalmann, has agreed to US$10 million in funding that can turn to US$20 million with warrant exercise which Biodexa's CEO believes can be triggered based on expected events. What could the market cap of Biodexa be with US$20 million cash to reach hard milestones on Biodexa's clinical trial or clinical trial ready programs addressing $12 billion with US$20 million to spend? What could licensing deals with the world's largest healthcare company(J&J) in 2023 be worth on xB3 and Q-Sphera if in 2023 the platforms are validated and an expansive pipeline can be financed in future years by Biodexa's lead clinical assets? Biodexa's lead asset for glioblastoma targets a $5 billion market providing great strength to the company and supportng a pipeline. What could the market cap of a $5 billion opportunity be worth as it is de-risked and hits the market? What could partnership deals on xB3 and Q-Sphera be worth given Biodexa's potential strength next year through clinical milestones. Could Biodexa be positioned to accelerate xB3 and Q-Sphera deals next year given its profile? There is a lot of speculation with this opportunity but a big and bold move is needed to escape the current crisis in biotech. There is a lot of dilution with the deal but it comes with a lot of upside and cash.